HIGHLIGHTS
- who: The Oncologist et al. from the Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA have published the paper: PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials, in the Journal: (JOURNAL) of March/23,/2022
- what: This study has an estimated enrollment of 387 patients with the primary outcome being rPFS . The primary outcome measure of this study will be an undetectable PSA rate at 12 months . domain of PSMA.45 225Ac-J591 was studied in a phase I clinical trial (NCT03276572) of patients with progressive mCRPC patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.